Epitalon (AEDG)

Synthetic Pineal Tetrapeptide — Telomerase Activation, Circadian Regulation & Geroprotection

Sleep Hygiene Learning Guide

Evidence at a Glance

Identity: Ala-Glu-Asp-Gly (AEDG); ~390 Da. A synthetic pineal tetrapeptide — the single defined active sequence distilled from the crude bovine pineal extract Epithalamin.

Developer / class: Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation & Gerontology. Synthetic pineal bioregulatory peptide; geroprotector.

Why it sits here: Dosed at night, it drives the pineal gland's own melatonin output and supports sleep, nighttime recovery, and downstream NAD mechanisms. The low-dose nighttime protocol (100–300 µg) is the sleep-relevant regimen. The same peptide also appears in the Circadian Rhythm group — this is its companion guide.

Core mechanisms: Telomerase (hTERT) activation; pineal/melatonin regulation (AANAT, pCREB, Clock–Cry2); epigenetic histone binding; antioxidant & anticarcinogenic effects.

Evidence base: 25+ years, predominantly Khavinson-group; mostly in vitro + animal; 14 peer-reviewed references, one clinical study. No RCTs, no human pharmacokinetics, little independent replication.

Regulatory: NOT FDA- or EMA-approved; not on any official drug registry, including Russia (where the parent extract Epithalamin is registered, but Epitalon is not). Investigational/off-label only.

⚠ **Signature caution:** In cancer cells, telomeres lengthen via ALT (Alternative Lengthening of Telomeres) with rising hTERT mRNA — a theoretical, unproven oncogenic signal. Cancer screening is the mandatory first step; any malignancy history is a contraindication.

Companion guide: *Epitalon is taught in two categories from the same source lecture. This Sleep Hygiene guide foregrounds its melatonin/nighttime-sleep role and the low-dose evening protocol; the mechanism, evidence, and safety content it shares with the Epitalon Circadian Rhythm guide are presented in full here so each guide stands alone.*

1. Peptide Profile

Where It Sits in the Sleep Hygiene Group

Within the sleep toolkit, Epitalon is the **pineal / melatonin driver** — the agent that works upstream on the gland that makes melatonin, rather than supplying melatonin directly. Dosed in the **evening**, it upregulates the melatonin machinery (AANAT) and supports the **night arm of the circadian clock**, which is the rationale for using a **low nighttime dose to improve sleep**, lift nocturnal melatonin output, and support the nighttime anabolic/recovery and NAD processes that depend on a clean melatonin rhythm. It is best understood as a **mechanistic adjunct within — not a replacement for — foundational sleep hygiene and behavioral sleep measures**, which (per the lecture's own framing) carry stronger evidence and should be addressed first. The same peptide is covered in the Circadian Rhythm group; here the emphasis is squarely on sleep.

Epitalon vs. Epithalamin — Two Different Things

This distinction is the single most important thing to keep straight. **Epithalamin** is the original crude bovine pineal **multi-peptide extract** — a complex mixture, dosed historically at ~50 mg, with the larger historical cohort dataset behind it, and it is a **registered preparation** in Russia.

Epitalon (AEDG) is the **single, synthetic, defined tetrapeptide** extracted conceptually from that mixture — reproducible, dosed at roughly **0.1 mg for equivalent melatonin normalization (a ~500-fold potency advantage)**, with more of the mechanistic in vitro data, and **not registered anywhere.** When older sources blur the two — or, as Dr. Seeds recounts, when product labeled one way was actually the other — dosing and evidence claims get scrambled. Treat them as separate agents.

The Khavinson Bioregulator Concept — and the Single-Institute Caveat

Epitalon belongs to the family of short "peptide bioregulators" developed by the Khavinson group, framed as tissue-specific signaling peptides that reach chromatin and modulate gene expression. The accompanying caveat runs through the entire evidence base: virtually all of it originates from that one group, is predominantly preclinical, and lacks independent Western replication. Dr. Seeds notes that, unlike Epithalamin and Thymalin, Epitalon is not on the official Russian drug registry — it is used within certain institutes under research protocols rather than as an approved drug.

The Melatonin / Sleep / Night-Repair Rationale

Mechanistically, the sleep rationale is concrete rather than nominal: Epitalon **upregulates AANAT** (the rate-limiting enzyme of melatonin synthesis) and **pCREB**, **modulates the molecular clock** (Clock down ~1.8-fold, Cry2 up ~2-fold in human leukocytes), and **normalizes melatonin** in elderly subjects at microgram doses — which is why a **low evening dose** is the sleep-relevant way to use it. Dr. Seeds's clinical observation is that the **300 µg nighttime dose** is the practical standard for raising melatonin production for sleep, supporting circadian-clock function, and driving downstream NAD mechanisms. Layered on top is its role as a **DNA-repair / genome-protective peptide** (reducing 8-OHdG), which he considers its most defensible short-term use during states of high oxidative stress — a recurring theme in the post-viral fatigue and poor-sleep presentations discussed below.

2. Modes of Action

The lecture frames Epitalon as a **master epigenetic regulator acting across six interconnected pathways.** The unifying idea: a tiny tetrapeptide reaches chromatin, opens it for transcription, and from that single upstream lever produces effects on telomeres, the pineal–melatonin axis, neuroprotection, antioxidant defense, and tumor biology.

1 · Telomere Biology

- **Normal cells:** reactivates the telomerase gene (**hTERT**) in telomerase-negative human fibroblasts, restoring activity absent in differentiated somatic cells. Dose-dependent telomere elongation — a **26-fold** telomerase increase in HMEC epithelial cells and a **4-fold** increase in IBR.3 fibroblasts (3-week treatment, 1 µg/mL). The most dramatic telomerase activation reported for any peptide.
- **Cancer cells:** a different pathway — **12-fold hTERT mRNA** rise in 21NT cells, but telomere elongation occurs via **ALT (Alternative Lengthening of Telomeres), not telomerase.** This normal-vs-cancer mechanistic split is the crux of the safety profile.

2 · Pineal – Melatonin Axis

- Upregulates **AANAT** and the **pCREB** transcription factor in pinealocytes — more prolonged and potent than Vilon at 3 hours.
- **Selectively protects aged pinealocytes** from degenerative change (tissue-specific longevity action); in aged rhesus monkeys, restored melatonin production and youthful cortisol rhythms.
- In elderly humans, **0.1 mg Epitalon produced the same melatonin normalization as 50 mg Epithalamin —** a ~500-fold potency advantage.

3 · Circadian / Epigenetic Clock

- Modulated clock genes in human leukocytes: **Clock decreased ~1.8-fold, Cry2 doubled —** confirming epigenetic clock-level activity in human cells and a plausible chronobiotic/longevity signaling role.
- **Conflicting datapoint (noted for honesty):** Djeridane et al. found no effect on melatonin secretion in isolated rat pineals in vitro — likely species/model context-dependence.

4 · Epigenetic Remodeling

- Preferentially binds **linker histones H1/6 (−64.51 kcal/mol)** and **H1/3 (−56.49 kcal/mol)**, competing with DNA binding sites.
- Induces **heterochromatin decondensation** near centromeres in aged human lymphocytes — in plain terms, the chromatin opens up so transcription can occur. Proposed mechanism: epigenetic rejuvenation of the aging chromatin landscape.

5 · Neuroprotection & Neurogenesis

- Neurogenic markers (**Nestin, GAP43, β-tubulin III, doublecortin**) increased **1.6–1.8x** in human stem cells; modulated AChE/BuChE activity; increased APP secretion ~20%; **reduced 8-OHdG** (DNA-damage protection) and increased dendritic branching complexity.

6 · Antioxidant Defense & Anti-Tumor Signaling

- **Antioxidant:** increased SOD, glutathione peroxidase, and glutathione-S-transferase in aging rats — a broad cytoprotective geroprotector profile.
- **Anti-tumor (rodent):** inhibited DMH-induced colon carcinogenesis; reduced HER-2/neu mRNA ~3.7-fold; maximum tumor size 33% lower vs controls; modulated proliferation and apoptosis. Note the tension with the ALT-in-cancer concern — the net oncologic effect in humans is unknown.

Pathway	Key effect	Evidence tier
Telomere biology	hTERT activation; 26x telomerase (HMEC); ALT in cancer cells	In vitro
Pineal–melatonin	AANAT/pCREB up; melatonin normalization at 0.1 mg	In vitro / animal / 1 clinical
Circadian clock	Clock down 1.8x, Cry2 up 2x in human leukocytes	In vitro (human cells)
Epigenetic	H1 histone binding; heterochromatin decondensation	In vitro

Pathway	Key effect	Evidence tier
Neuroprotection	Neurogenic markers up 1.6–1.8x; 8-OHdG reduced	In vitro
Antioxidant / anti-tumor	SOD/GPx up; HER-2/neu mRNA down 3.7x; tumor size −33%	Animal

Mechanistic takeaway: One upstream action — reaching chromatin and modulating gene expression — radiates into telomere, circadian, neural, redox, and tumor biology. That breadth is what makes Epitalon compelling, and also why no single clinical endpoint has been cleanly validated: the same reach that elongates telomeres in normal cells corresponds to ALT in cancer cells.

3. Seven Points of Clinical Relevance

1. A sleep / melatonin and DNA-repair peptide first.
Its most defensible clinical uses, in Dr. Seeds's framing, are low-dose evening support for sleep and melatonin output, and short-term support during states of high oxidative stress (tracking 8-OHdG) — not as an open-ended anti-aging therapy. It is an adjunct within a sleep-hygiene program, not a primary hypnotic.

2. Epitalon is not Epithalamin — do not conflate them.
Potency differs roughly 500-fold, regulatory status differs (Epithalamin is registered in Russia; Epitalon is not), and the strongest human outcome data belong to Epithalamin or to multi-agent regimens — not to single-agent Epitalon.

3. The ALT-in-cancer signal sets a hard safety rule.
Because cancer cells can lengthen telomeres via ALT with rising hTERT mRNA, cancer screening is a non-negotiable first step and any malignancy history is a contraindication — even though the real-world risk is unproven.

4. Evening dosing is the sleep-relevant approach.
Aligning administration with the melatonin rhythm (AANAT upregulation) is the logic behind bedtime dosing; the low microgram nighttime dose (~100–300 µg, with 300 µg the practical standard) specifically targets sleep, melatonin output, circadian alignment, and NAD mechanisms — distinct from the high-dose longevity cycles.

5. All human use is investigational and off-label.
Never present Epitalon as a validated longevity, anti-aging, or cancer-prevention therapy. Frame it as a promising research-stage peptide with mechanisms ahead of its clinical data.

6. Single-institute provenance with no RCTs or PK.
Treat every efficacy claim as preliminary. There are no Phase I–III trials, no human pharmacokinetics, and essentially no independent replication — so meticulous documentation and biomarker monitoring substitute for a validated evidence base.

7. Multi-agent regimens confound attribution.

The most cited outcomes (e.g., Thymalin + annual Epitalon → 4.1-fold mortality reduction) come from combinations that make single-agent conclusions impossible. Start single-agent before layering combinations, and document every concurrent intervention.

4. Dosing & Delivery

All dosing is empirical and off-label — no FDA-approved protocol exists. What follows are the protocols Dr. Seeds describes in current clinical practice. For sleep, the **low-dose nighttime regimen (A)** is the relevant one; the daily and high-dose cycles are included for completeness, along with the historical account that explains why such a wide dose range coexists.

Route, Timing & Handling

- **Route:** subcutaneous, rotating sites (abdomen, thighs, upper arms).
- **Timing:** evening/bedtime preferred for melatonin synergy; a morning option exists when the goal is daytime circadian/DNA-repair support.
- **Reconstitution & storage:** bacteriostatic water; **do not shake — and be cautious even swirling**, given the fragility of the peptide. Many compounding pharmacies supply it pre-reconstituted. Refrigerate (2–8°C) after reconstitution; discard if cloudy.

Three Protocols in Clinical Use

A · Low-dose nighttime (sleep — primary for this category). ~100–300 µg (300 µg is the common standard) at night — or in the morning — to drive melatonin, support the circadian clock, and feed NAD mechanisms. This range traces back to a mouse→human translation (~2.4 µg/kg, i.e. ~170–200 µg for a 70–90 kg person). Using ~100 µg daily for 10 days approximates the original Epithalamin study translation.

B · Continuous daily. ~3 mg/day, used consecutively and then cycled. Dr. Seeds's suggested rotation when dosing daily is roughly three months on, then at least ~6 weeks off before resuming.

C · High "mega" dosing (legacy, Epithalamin-derived). 5–10 mg/day SC over 10–20 consecutive days, 2–3 cycles per year, with 4–6 months off between cycles — equivalent to the historical 50–100 mg-over-10-days Epithalamin protocols. This is the regimen with the largest (uncontrolled, anecdotal) real-world track record.

Context	Dose	Duration / cycling
Low-dose nighttime (SC)	100–300 µg (300 µg common)	Daily, or 10-day courses; 3x/year
Continuous daily (SC)	~3 mg/day	~3 months on / ~6 weeks off
High "mega" dose (SC)	5–10 mg/day	10–20 days; 2–3 cycles/yr; 4–6 mo off
Research — animal (SC)	1 µg/mouse	5 days/month (Anisimov protocols)
In vitro	0.01–1.0 µg/mL	1–3 weeks continuous
Clinical (melatonin study)	0.1 mg	Short course = 50 mg Epithalamin

Historical Note on Sourcing & Dosing — Why the Range Is So Wide

Dr. Seeds gives an unusually candid account of the early "Wild West" peptide era. For years, much of what was sold and labeled as **Epitalon was actually Epithalamin** (and vice versa), because sourcing and validation were unreliable. To avoid harm amid that confusion, he deliberately kept the established **Epithalamin dosing protocol** (the ~50–100 mg-over-10-days regimens) in play — which is why "Epitalon" was, in practice, dosed at very high levels for many years.

His clinically relevant observations from that period: across thousands of patients dosed at those high levels, **no safety signals or immune toxicities emerged**, and he reports notable benefit in **post-COVID and post-Lyme chronic fatigue and neurocognitive presentations** — working, in his view, through circadian-clock and downstream NAD/melatonin mechanisms — where the low microgram dosing underperformed. The 2013 comparison paper later established the true potency relationship (0.1 mg ≈ 50 mg Epithalamin).

How to read this: it is a large, real-world, uncontrolled experience that arose from a labeling error, not validated trial evidence. It is genuinely useful context for understanding why high-dose protocols exist and appear well tolerated — but it does not substitute for the Phase I–III data that remain absent.

Dr. Seeds's own bottom line: he favors the **higher-dose protocols** based on his long clinical experience, while urging clinicians to know exactly where each dose sits relative to the published studies and to **keep meticulous personal records** (route, dose, cycling, duration, and clinical response) so the field can assemble better evidence over time.

5. Evidence Profile

What the Evidence Supports

- Telomerase activation and dose-dependent telomere elongation in **normal human cells in vitro** (26x HMEC, 4x IBR.3).
- **11–31% mean lifespan extension** across multiple animal species (Drosophila, mice, rats), effective at concentrations far below melatonin.
- Pineal protection and melatonin-axis modulation; **0.1 mg ≈ 50 mg Epithalamin** for melatonin normalization in elderly humans.
- Epigenetic activity (histone binding, Clock–Cry2 modulation), antioxidant enzyme upregulation, neurogenic-marker increases, and rodent anti-tumor activity.

Study / model	Finding	Tier
HMEC (Al-dulaimi 2025)	26-fold telomerase increase (1 µg/mL, 3 wk)	In vitro
21NT cancer cells	12-fold hTERT mRNA; telomere ↑ via ALT	In vitro
Multi-species (Anisimov)	11–31% mean lifespan extension	Animal
Elderly humans (2013)	Melatonin normalization at 0.1 mg	Clinical (1 study)

Study / model	Finding	Tier
Cohort n=266 (Khavinson)	1.6–4.1x mortality reduction (multi-agent)	Observational
HER-2/neu mice	Tumor size −33%; HER-2/neu mRNA ⊓3.7x	Animal

What Remains Unproven

- Any human longevity or anti-aging effect — untested by RCT; no benefit beyond placebo demonstrated in any blinded human trial.
- Optimal human dose, schedule, and duration; human pharmacokinetics; long-term safety beyond uncontrolled observation.
- Whether the ALT signal translates into real human cancer risk; drug interactions; benefit in diseased populations; head-to-head vs other telomerase activators; independent replication of the Khavinson data.

⚠ Critical Gaps

- No Phase I–III trials in ClinicalTrials.gov or EudraCT for Epitalon specifically.
- No human PK and no long-term safety registry — long-term risk is undefined, not reassured.
- ALT activation in cancer cells (in vitro) — theoretical oncogenic concern of unknown real-world weight.
- Essentially all data from one group; no independent replication; multi-agent regimens block single-agent attribution.

6. Clinical Considerations

Contraindications & Precautions

- **Absolute:** active or historical malignancy of any type (ALT risk); pregnancy or lactation; pediatric patients (<18, unstudied).
- **Relative:** strong family history of cancer; known telomerase-driven cancers; patients on oncologic agents; uncontrolled systemic illness.
- **Interaction cautions (all uncharacterized):** immunosuppressants, anticoagulants, mTOR inhibitors. No interaction database exists. Renal/hepatic impairment and immunocompromise warrant added caution.

Safety Profile

- Generally well tolerated in published (uncontrolled) studies; no serious adverse events reported; mild, transient injection-site reactions possible.
- Transient sleep-pattern changes possible (melatonin pathway) — monitor.
- Long-term human safety entirely unknown; all reassurance derives from the Khavinson group and from uncontrolled real-world experience, without independent replication.

Monitoring Framework

- **Baseline:** cancer screening (rule out malignancy first), melatonin and inflammatory markers, telomere length if available.
- **Cycle end (day 10–20):** sleep quality, injection-site evaluation, tolerability and early adverse effects.
- **3 months post-cycle:** immune panels, hormone levels (melatonin, cortisol), inflammatory markers.
- **Annual:** serial telomere length and methylation clock (limited current clinical utility), cancer surveillance, full metabolic panel.

Regulatory & Consent

Not approved by FDA, EMA, or any major regulatory body, and not on Russia's drug registry (unlike Epithalamin and Thymalin). Every human use is investigational and off-label and requires explicit, documented informed consent, including the experimental status, the absence of long-term safety data, and the theoretical cancer signal. Stronger-evidence longevity measures (lifestyle, diet, exercise) should be discussed; patients may withdraw at any time.

7. Final Note

Within the sleep toolkit, Epitalon is the **pineal / melatonin driver —** and, more broadly, arguably the most mechanistically far-reaching small peptide in longevity research: a single defined tetrapeptide that touches telomere biology, the pineal–melatonin axis, epigenetic chromatin remodeling, neuroprotection, antioxidant defense, and anti-tumor signaling. Its sleep credentials are concrete — AANAT upregulation, Clock–Cry2 modulation, and melatonin normalization at roughly 1/500th the dose of crude Epithalamin — which is why a **low evening dose (~300 µg)** is the sensible way to use it for sleep, and why it sits in both the Sleep Hygiene and Circadian Rhythm groups.

The honest framing is that Epitalon sits almost entirely in the **preclinical** realm. There are no Phase I–III trials, no human pharmacokinetics, and the most persuasive human outcomes belong to Epithalamin or to multi-agent regimens that make single-agent attribution impossible, with independent replication absent. Its most defining feature is double-edged: the same telomere reach that produces a 26-fold telomerase increase in normal cells corresponds to **ALT in cancer cells —** a theoretical, unproven oncogenic signal that nonetheless makes cancer screening the non-negotiable first step and any malignancy history a contraindication.

The updated dosing story adds important real-world texture: because early product was frequently mislabeled, **high-dose (Epithalamin-derived) Epitalon protocols accumulated years of uncontrolled experience without obvious safety signals**, and Dr. Seeds reports his strongest clinical impressions — in post-viral and post-Lyme fatigue, poor sleep, and neurocognitive states — at those higher doses. That experience is valuable context, not validation. For the clinician, Epitalon is best understood as a research-stage peptide with a uniquely broad mechanistic story and a genuine sleep/melatonin and DNA-protective rationale — most defensibly used at **low evening doses for sleep** and short-term in oxidative-stress states (tracking 8-OHdG), as an **adjunct within a sleep-hygiene program** rather than a standalone hypnotic — and only investigationally, after cancer screening, with full informed consent and meticulous documentation.

Bottom line: A synthetic pineal tetrapeptide (AEDG) used in the sleep toolkit as the upstream melatonin driver — the most potent telomerase activator among peptides, with melatonin/Clock–Cry2 effects, broad antioxidant/neuroprotective mechanisms, and 11–31% lifespan extension across animal species — but ZERO Phase I–III trials, no human PK, and a signature ALT-in-cancer signal that makes malignancy history a contraindication. For sleep, use the low evening dose (~300 µg) as an adjunct within a sleep-hygiene program. Cancer screening is mandatory first. Distinct from Epithalamin (the crude pineal extract). Research/investigational only.

Selected References

[1] Khavinson VKh, et al. Peptides and ageing. Neuro Endocrinol Lett. 2002;23(Suppl 3):11–144. [Review]

[2] Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. [In Vitro]

[3] Anisimov VN, et al. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Lett. 2002;183(1):1–8. [Animal Study]

[4] Anisimov VN, et al. Inhibitory effect of the peptide epitalon on spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7–10. [Animal Study]

[5] Kossoy G, et al. Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis. Int J Mol Med. 2003;12(4):473–477. [Animal Study]

[6] Khavinson VK, et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000;120(1–3):141–149. [Animal Study]

[7] Anisimov VN, et al. Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats. Mech Ageing Dev. 1998;103(2):123–132. [Animal Study]

[8] Anisimov VN, et al. Epithalon inhibits tumor growth and HER-2/neu expression in breast tumors in transgenic mice. Bull Exp Biol Med. 2002;133(2):167–170. [Animal Study]

[9] Khavinson V, et al. AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: epigenetic mechanism. Molecules. 2020;25(3):609. [In Vitro]

[10] Yue X, et al. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging (Albany NY). 2022;14(7):3191–3202. [In Vitro/Animal]

[11] Araj SK, et al. Overview of Epitalon — highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691. [Review]

[12] Al-dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. [In Vitro]

[13] Anisimov VN, et al. Twenty years of study on effect of pineal peptide preparation epithalamin in gerontology and oncology. Ann N Y Acad Sci. 1994;719:483–493. [Review]

[14] Antoniuk-Shcheglova I. Correction of melatonin-producing function of the pineal gland in the elderly with substitutive doses and epiphysis peptide drugs. Problems of Endocrine Pathology. 2013;4. [Clinical Trial]

For educational and research purposes only. Not medical advice. Epitalon (AEDG) is NOT FDA- or EMA-approved and is not on any official drug registry, including Russia (where the parent extract Epithalamin is registered, but Epitalon is not). All human use is experimental and off-label. There are no Phase I–III trials and no human pharmacokinetic data; essentially all evidence derives from the Khavinson group without independent replication. Long-term safety is unknown, and an ALT signal in cancer cells makes cancer screening mandatory and malignancy history a contraindication. Based on lecture materials by William Seeds, MD — SSRP Institute | Cellular Medicine Education.